Jaguar Health, Inc. has filed a Form 8-K announcing that it will effect a reverse stock split of its common stock at a ratio of 1-for-25. The split was approved by stockholders at a special meeting held on November 6, 2026, and is intended to support the company’s compliance with Nasdaq listing standards.
The reverse split is scheduled to become effective at 12:01 a.m. Eastern Time on Tuesday, November 24, 2026. At that time, every 25 shares of issued and outstanding common stock will automatically be reclassified into one share of common stock. The par value per share will remain unchanged.
Following the split, the company’s common stock will continue to trade on The Nasdaq Capital Market under the ticker symbol "JAGX". The new CUSIP number for the stock is 47010C839. Trading will begin on a split-adjusted basis when the market opens on November 24, 2026.
The reverse split will reduce the number of shares issuable upon the exercise or vesting of outstanding stock options and warrants in proportion to the 1-for-25 ratio. This will cause a corresponding increase in the conversion and exercise prices for those instruments. The number of shares reserved for issuance under the company’s equity compensation plans will also be reduced proportionately. No fractional shares will be issued; stockholders who would otherwise receive a fractional share will receive a cash payment in lieu thereof.
Equiniti Trust Company, LLC is acting as the exchange agent for the transaction. Stockholders who hold their shares in "street name" through a broker or bank are not required to take any action. Stockholders who hold physical certificates will receive instructions from the exchange agent regarding the exchange of their certificates.